Trial Profile
Establishing a Neo-Adjuvant Platform for Developing Targeted Agents: Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 28 Feb 2024 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 28 Feb 2024 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2025.
- 28 Feb 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.